Biopharma | June 29, 2025
Sartorius expands manufacturing and R&D capacities for bioprocess solutions in France
Extended lab space for product development, customer demos, and training
Extended lab space for product development, customer demos, and training
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The company uses iPS cells to develop treatments for diseases relating to the kidney
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Development services for gene and cell therapies is planned to begin first in 2025
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
